BRCA1 and breast cancer: In particular, given the rise in precision-personalised medicine and the successful N-of-1 treatment approach demonstrated in the I-PREDICT study (47), BRCA1 methylation beyond OV and BC should be explored as a potential biomarker for PARPi sensitivity, particularly in the CN high endometrial subgroup, where we observed BRCA1 methylation at >3% frequency.